Immunomodulators

This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.

Fatigue affects a large majority of pediatric IBD patients and is linked to worse quality of life even when disease is in remission, so it’s a common problem families and clinicians will likely encounter. Understanding...

This is a patient-friendly summary explaining what Crohn’s disease is, common symptoms, and typical treatment and monitoring approaches. It can help people recognize symptoms and understand basic management options.

Market reports can signal which drugs, companies, and biosimilars are becoming more available and may affect access and cost. Announcements about biosimilars could influence treatment affordability and prescribing...

This study suggests LVV can occur in people with IBD at younger ages and with distinct vascular findings, and it may arise even when gut disease is in remission. That matters for awareness, diagnosis, and coordination...

You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.

This study suggests a common genetic marker (HLA‑DQA1*05) may help explain why some children stop responding to anti‑TNF drugs and could eventually guide who might benefit from adding methotrexate or closer monitoring.

This article is a market research summary about the global Crohn’s disease treatment market — it describes sales forecasts, industry players, and market trends rather than new clinical findings or patient-focused...

This gives adults with moderately to severely active Crohn’s disease another FDA‑approved biologic option, including for people who did not respond to or could not tolerate other therapies.

The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...